About biolinerx - BLRX
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
BLRX At a Glance
BioLineRx Ltd.
Modi'in Technology Park
Modi'in, HaMerkaz 7177871
| Phone | 972-8-642-9100 | Revenue | 1.19M | |
| Industry | Pharmaceuticals: Major | Net Income | -1,184,321.25 | |
| Sector | Health Technology | Employees | 24 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
BLRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 9.569 |
| Price to Book Ratio | 0.662 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.59 |
| Enterprise Value to Sales | 4.88 |
| Total Debt to Enterprise Value | 1.749 |
BLRX Efficiency
| Revenue/Employee | 49,556.705 |
| Income Per Employee | -49,346.719 |
| Receivables Turnover | 2.608 |
| Total Asset Turnover | 0.03 |
BLRX Liquidity
| Current Ratio | 1.953 |
| Quick Ratio | 1.776 |
| Cash Ratio | 1.722 |
BLRX Profitability
| Gross Margin | 36.186 |
| Operating Margin | -871.78 |
| Pretax Margin | -171.695 |
| Net Margin | -99.576 |
| Return on Assets | -2.968 |
| Return on Equity | -7.482 |
| Return on Total Capital | -4.178 |
| Return on Invested Capital | -5.025 |
BLRX Capital Structure
| Total Debt to Total Equity | 55.781 |
| Total Debt to Total Capital | 35.808 |
| Total Debt to Total Assets | 24.814 |
| Long-Term Debt to Equity | 29.88 |
| Long-Term Debt to Total Capital | 19.181 |